Last reviewed · How we verify

IPTp-dihydroartemisinin-piperaquine plus metronidazole

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

IPTp-dihydroartemisinin-piperaquine plus metronidazole is a Antimalarial combination with antibiotic/antiprotozoal agent Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions, Prevention of malaria and associated infections during pregnancy. Also known as: Flagyl, D-ARTEPP®.

This combination drug uses dihydroartemisinin-piperaquine to treat malaria parasites and metronidazole to treat bacterial and protozoal infections, administered as intermittent preventive therapy in pregnancy.

This combination drug uses dihydroartemisinin-piperaquine to treat malaria parasites and metronidazole to treat bacterial and protozoal infections, administered as intermittent preventive therapy in pregnancy. Used for Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions, Prevention of malaria and associated infections during pregnancy.

At a glance

Generic nameIPTp-dihydroartemisinin-piperaquine plus metronidazole
Also known asFlagyl, D-ARTEPP®
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntimalarial combination with antibiotic/antiprotozoal agent
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Dihydroartemisinin-piperaquine is an artemisinin-based combination therapy that kills malaria parasites through multiple mechanisms including generation of reactive oxygen species and inhibition of parasite protein synthesis. Metronidazole is a nitroimidazole that generates cytotoxic free radicals to eliminate anaerobic bacteria and certain protozoa. Together, this combination aims to prevent malaria and associated infections during pregnancy (IPTp = Intermittent Preventive Therapy in pregnancy).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IPTp-dihydroartemisinin-piperaquine plus metronidazole

What is IPTp-dihydroartemisinin-piperaquine plus metronidazole?

IPTp-dihydroartemisinin-piperaquine plus metronidazole is a Antimalarial combination with antibiotic/antiprotozoal agent drug developed by London School of Hygiene and Tropical Medicine, indicated for Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions, Prevention of malaria and associated infections during pregnancy.

How does IPTp-dihydroartemisinin-piperaquine plus metronidazole work?

This combination drug uses dihydroartemisinin-piperaquine to treat malaria parasites and metronidazole to treat bacterial and protozoal infections, administered as intermittent preventive therapy in pregnancy.

What is IPTp-dihydroartemisinin-piperaquine plus metronidazole used for?

IPTp-dihydroartemisinin-piperaquine plus metronidazole is indicated for Intermittent preventive therapy in pregnancy (IPTp) for malaria prevention in pregnant women in malaria-endemic regions, Prevention of malaria and associated infections during pregnancy.

Who makes IPTp-dihydroartemisinin-piperaquine plus metronidazole?

IPTp-dihydroartemisinin-piperaquine plus metronidazole is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

Is IPTp-dihydroartemisinin-piperaquine plus metronidazole also known as anything else?

IPTp-dihydroartemisinin-piperaquine plus metronidazole is also known as Flagyl, D-ARTEPP®.

What drug class is IPTp-dihydroartemisinin-piperaquine plus metronidazole in?

IPTp-dihydroartemisinin-piperaquine plus metronidazole belongs to the Antimalarial combination with antibiotic/antiprotozoal agent class. See all Antimalarial combination with antibiotic/antiprotozoal agent drugs at /class/antimalarial-combination-with-antibiotic-antiprotozoal-agent.

What development phase is IPTp-dihydroartemisinin-piperaquine plus metronidazole in?

IPTp-dihydroartemisinin-piperaquine plus metronidazole is in Phase 3.

What are the side effects of IPTp-dihydroartemisinin-piperaquine plus metronidazole?

Common side effects of IPTp-dihydroartemisinin-piperaquine plus metronidazole include Nausea, Vomiting, Abdominal pain, Metallic taste (metronidazole), Headache.

Related